21 November 2022>: Clinical Research
Long-Term Effect of Pancreaticoduodenectomy Combined with Revascularization for Resectable Pancreatic Carcinoma in Elderly Patients
Jiali Yang 1ABCDEF* , Zhengrong Xu 2ABCD* , Junfeng Zhang 1CD , Yao Zheng 1CD , Jianyou Gu 1AC , Qiang Zhou 1CD , Xianxing Wang 1CD , Shixiang Guo 1DF , Hongyu Zhang 3AD , Shengkai Chen 1ADG* , Huaizhi Wang 1ADG*DOI: 10.12659/MSM.938443
Med Sci Monit 2022; 28:e938443
Table 4 Analysis of the OS and PFS of PDAC patients who underwent PDR according to age.
Variables | OS | |||
---|---|---|---|---|
Age <60 y (n=97) | 60 y ≤ Age <70 y (n=51) | Age ≥70 y (n=22) | P value | |
Preoperative CA19-9 ≥200 IU/L | 9.2 (7.638–10.762) | 7.1 (3.892–10.308) | 8.1 (3.587–12.613) | 0.474 |
Vascular invasion site | ||||
PV | 14.7 (0.000–33.238) | – | 17.9 (6.858–28.942) | 0.436 |
Confluence of PV-SMV | 7.2 (5.343–9.057) | 8.9 (6.401–11.399) | 7.0 (4.690–9.310) | 0.673 |
SMV | 11.5 (8.386–14.614) | 8.4 (5.619–11.181) | 9.1 (4.941–13.259) | 0.049 |
Venous reconstruction | ||||
Interposition graft | 9.7 (8.771–10.629) | 7.1 (5.566–8.634) | 6.1 (0.220–11.980) | 0.628 |
End-to-end anastomosis | 9.6 (7.717–11.283) | 9.2 (7.048–11.352) | 8.3 (6.469–10.131) | 0.693 |
Primary closure | 14.7 (0.000–40.063) | – | – | 0.293 |
T stage 1/2 | 11.2 (8.595–13.805) | 8.9 (7.783–9.927) | 9.1 (5.253–12.947) | 0.509 |
N stage 1/2 | 9.2 (5.764–12.636) | 8.4 (6.051–10.749) | 5.9 (0.000–12.968) | 0.833 |
TNM stage | ||||
I/II | 9.7 (7.718–11.682) | 8.9 (7.845–9.955) | 10.8 (7.267–14.333) | 0.736 |
III/IV | 7.1 (1.329–12.871) | 6.7 (3.580–9.820) | 3.0 (0.439–5.561) | 0.479 |
Degree of differentiation | ||||
Well | 12.1 (8.278–15.922) | 6.1 (5.620–6.580) | 10.9 (0.000–34.329) | 0.345 |
Moderate | 9.9 (8.036–11.735) | 10.1 (8.395–11.805) | 8.3 (6.750–9.850) | 0.451 |
Poor | 5.8 (5.143–6.457) | 6.9 (5.256–8.544) | 4.3 (0.000–11.982) | 0.977 |
Postoperative adjuvant antineoplastic therapy | 14.7 (9.175–20.225) | 9.2 (5.973–12.427) | 13.1 (8.591–17.609) | 0.184 |
( | ≤ | ≥ ( | ||
Preoperative CA19-9 ≥200 IU/L | 6.3 (4.389–8.211) | 5.0 (2.805–7.195) | 6.5 (0.000–13.679) | 0.957 |
Vascular invasion site | ||||
PV | 7.1 (2.353–11.847) | – | 17.9 (6.858–28.942) | 0.095 |
Confluence of PV-SMV | 5.0 (3.793–6.207) | 6.0 (4.736–7.264) | 5.7 (3.904–7.496) | 0.998 |
SMV | 7.6 (6.362–8.838) | 6.2 (1.586–10.814) | 8.4 (4.395–9.057) | 0.226 |
Venous reconstruction | ||||
Interposition graft | 5.9 (2.491–9.309) | 4.6 (3.723–5.477) | 5.7 (0.000–11.580) | 0.397 |
End-to-end anastomosis | 6.9 (6.444–7.356) | 7.8 (4.997–10.603) | 8.3 (4.870–11.730) | 0.740 |
Primary closure | 12.4 (0.000–34.020) | – | – | 0.303 |
T stage 1/2 | 7.8 (6.549–9.051) | 6.1 (3.303–8.897) | 8.4 (4.747–12.053) | 0.854 |
N stage 1/2 | 5.3 (3.287–7.313) | 5.8 (3.804–7.796) | 3.0 (0.000–8.544) | 0.879 |
TNM stage | ||||
I/II | 7.0 (5.808–8.192) | 6.0 (4.671–7.329) | 9.1 (5.744–12.456) | 0.472 |
III/IV | 4.0 (0.945–7.055) | 6.7 (2.021–11.379) | 3.0 (0.439–5.561) | 0.711 |
Degree of differentiation | ||||
Well | 6.7 (0.624–12.776) | 6.1 (5.620–6.580) | 10.9 (0.000–36.345) | 0.416 |
Moderate | 7.0 (5.622–8.378) | 8.2 (5.818–10.582) | 8.3 (4.271–12.329) | 0.918 |
Poor | 5.0 (3.028–6.972) | 4.0 (2.708–5.292) | 4.3 (0.000–9.485) | 0.225 |
Postoperative adjuvant antineoplastic therapy | 7.9 (6.230–9.570) | 6.0 (3.849–8.151) | 11.0 (6.921–15.079) | 0.281 |
Postoperative adjuvant therapy includes chemotherapy, radiotherapy, biological therapy, traditional Chinese medicine therapy, etc. |